[HTML][HTML] Evidence-based pharmacological treatment options for ADHD in children and adolescents

K Mechler, T Banaschewski, S Hohmann… - Pharmacology & …, 2022 - Elsevier
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder
characterized by inattention, hyperactivity, and impulsivity, causing functional impairment. Its …

Opportunities and limitations of genetically modified nonhuman primate models for neuroscience research

G Feng, FE Jensen, HT Greely… - Proceedings of the …, 2020 - National Acad Sciences
The recently developed new genome-editing technologies, such as the CRISPR/Cas
system, have opened the door for generating genetically modified nonhuman primate (NHP) …

Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges

AE Williams, JM Giust, WG Kronenberger… - … disease and treatment, 2016 - Taylor & Francis
Attention-deficit hyperactivity disorder (ADHD) has a prevalence rate of 7%–9% in the
general population of children. However, in children with epilepsy, ADHD has been found to …

Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis

PY Pan, U Jonsson, SSŞ Çakmak, A Häge… - Psychological …, 2022 - cambridge.org
There is mixed evidence on the association between headache and attention-
deficit/hyperactivity disorder (ADHD), as well as headache and ADHD medications. This …

[HTML][HTML] The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic …

F Catalá-López, B Hutton, A Núñez-Beltrán… - Systematic reviews, 2015 - Springer
Background Attention deficit hyperactivity disorder (ADHD) is one of the most common
neurodevelopmental disorders of children and adolescents, with a significant impact on …

[HTML][HTML] Guanfacine extended release: a new pharmacological treatment option in Europe

M Huss, W Chen, AG Ludolph - Clinical drug investigation, 2016 - Springer
Children/adolescents with attention-deficit/hyperactivity disorder (ADHD) may have a poor or
inadequate response to psychostimulants or be unable to tolerate their side-effects; …

Pediatric pharmacoepidemiology-safety and effectiveness of medicines for ADHD

A Clavenna, M Bonati - Expert Opinion on Drug Safety, 2017 - Taylor & Francis
Introduction: Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral
disorder in children and adolescents that comprises core symptoms of developmentally …

[HTML][HTML] The blind spot of pharmacology: a scoping review of drug metabolism in prematurely born children

ML Mørk, JT Andersen, U Lausten-Thomsen… - Frontiers in …, 2022 - frontiersin.org
The limit for possible survival after extremely preterm birth has steadily improved and
consequently, more premature neonates with increasingly lower gestational age at birth now …

Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions

GW Mattingly, J Wilson, L Ugarte, P Glaser - CNS spectrums, 2021 - cambridge.org
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that
manifests in childhood and can persist into adolescence and adulthood. Impairments …

A systematic meta-review of systematic reviews on attention deficit hyperactivity disorder

A Chaulagain, I Lyhmann, A Halmøy… - European …, 2023 - cambridge.org
BackgroundThere are now hundreds of systematic reviews on attention deficit hyperactivity
disorder (ADHD) of variable quality. To help navigate this literature, we have reviewed …